IKT Inhibikase Therapeutics, Inc.
Financings ·
On July 29, 2026, RA Capital Healthcare Fund exchanged 18,030,000 Inhibikase common shares for a pre-funded warrant on the same number of shares. The warrant carries a 9.99% ownership limit, and the filing does not say why the exchange was made.
Inhibikase paid $15.0 million for CorHepta in 4,979,101 newly issued shares, with part held in escrow or tied to a milestone. The 8-K names no bank, placement agent or financial adviser for the stock issuance.
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, starting with pulmonary arterial hypertension, or PAH, which is an orphan indication. Its lead product candidate is IKT-001, a prodrug of imatinib. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders, and the company notes that after more than 20 years of clinical use it has a well-characterized safety profile. The first reported use of imatinib in PAH occurred in 2005. PAH is a progressive, life-threatening disease that affects approximately 50,000 Americans. The company describes aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor known as c-Kit, as implicated in the disease. Inhibikase has completed a non-human primate safety study and a bioequivalence clinical study in healthy volunteers to determine the doses of IKT-001. It plans to initiate Phase 3 trials in PAH in multiple countries to support regulatory approval. Its subsidiaries are IKT Securities Corporation and CorHepta Pharmaceuticals, Inc.
| Product or program | What it is | Stage |
|---|---|---|
| IKT-001 | Prodrug of imatinib for pulmonary arterial hypertension, an orphan indication | Phase 3 planned in PAH |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | |
| Research and development | $29.8 million | $17.2 million |
| Net income (loss) | -$48.3 million | -$27.5 million |
| Cash from operations | -$27.8 million | -$19.1 million |
| Cash and equivalents | $178.8 million | $97.5 million |
| Short-term investments | $39.5 million | $41.1 million |
Our latest story on this, dated Feb 24, 2025: "Inhibikase acquires CorHepta in merger, paying $15.0 million in 4,979,101 shares of stock". The story links the filing or release it is based on. Read the story.
Inhibikase Therapeutics, Inc. trades under the ticker IKT on NASDAQ.
Inhibikase Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Inhibikase Therapeutics, Inc. is 1750149. Its filings are on SEC EDGAR.
139,535,900 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Inhibikase Therapeutics, Inc. under United States.
Our directory classifies Inhibikase Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Inhibikase Therapeutics, Inc. is US45719W2052.
aibio.space lists Inhibikase Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, starting with pulmonary arterial hypertension, or PAH, which is an orphan indication. Its lead product candidate is IKT-001, a prodrug of imatinib.
IKT-001: Prodrug of imatinib for pulmonary arterial hypertension, an orphan indication Stage: Phase 3 planned in PAH.
Inhibikase Therapeutics, Inc. reported a net loss of $48.3 million for the fiscal year ended Dec 31, 2025, and used $27.8 million of cash in operations, per its annual report to the SEC.
$29.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$159.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio